Cleveland Clinic Foundation-Cole Eye Institute — Cleveland, Ohio

Cleveland Clinic Foundation-Cole Eye Institute is a clinical research site located in Cleveland, Ohio, United States 44191.

Crixeo Clinical Trials Trust Score: 19/100 (FAILING). This profile has not yet been claimed by the site owner.

Cleveland Clinic Foundation-Cole Eye Institute has participated in 18 clinical trials with 3 currently active.

Therapeutic areas: Noninfectious Uveitis, Macular Degeneration, Geographic Atrophy (GA).

Sponsors: Gilead Sciences, Genentech, Inc., ONL Therapeutics.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Cleveland

Browse all research sites in Ohio · View every site in Cleveland

Sponsor Feasibility Report

Trust Score: 19/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Cleveland Clinic Foundation-Cole Eye Institute?

Cleveland Clinic Foundation-Cole Eye Institute has a Crixeo Trust Score of 19/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Cleveland Clinic Foundation-Cole Eye Institute conducted?

Cleveland Clinic Foundation-Cole Eye Institute has 18 clinical trials on record, with 3 currently active. Their work covers Noninfectious Uveitis, Macular Degeneration, Geographic Atrophy (GA).

Is Cleveland Clinic Foundation-Cole Eye Institute accredited by Crixeo Clinical Trials?

Cleveland Clinic Foundation-Cole Eye Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Cleveland Clinic Foundation-Cole Eye Institute?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.